Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study.

AIMS Retrospective studies and post hoc analyses have suggested that mild elevations in the creatine kinase-MB (CK-MB) isoenzyme following percutaneous coronary intervention (PCI) may be associated with an increased risk of death in the long term. However, this finding is still controversial, and the prognostic significance of elevations of more sensitive markers of myocardial damage, such as the cardiac troponins, has not been established. In this multicentre prospective cohort study, we evaluated the influence of post-procedural elevations of CK-MB and troponin I (cTnI) on long-term mortality. METHODS AND RESULTS The CK-MB and PCI study included 3494 consecutive patients undergoing PCI from February 2000 to October 2000 in 16 Italian tertiary centres. Blood samples were collected at baseline, and at 8-12 and 18-24 h after the procedure, and were analysed in a core biochemistry laboratory. CK-MB elevation was detected in 16% of the patients, and was associated with increased 2-year mortality [7.2 vs. 3.8%; odds ratio (OR): 1.9; 95% confidence interval (CI): 1.3-2.8; P<0.001). The degree of CK-MB elevation (peak CK-MB ratio) independently predicted the risk of death (adjusted OR per unit: 1.04; 95% CI: 1.01-1.07; P=0.009). A cTnI elevation was detected in 44.2% of the cases and was not associated with a significant increase in mortality (4.9 vs. 4.0%; OR: 1.2; 95% CI: 0.9-1.7; P=0.2). CONCLUSION Post-procedural elevations of CK-MB, but not cTnI, influence 2-year mortality.

[1]  W. Takahashi,et al.  [High-sensitivity C-reactive protein]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[2]  I. Porto,et al.  Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. , 2005, European heart journal.

[3]  J. Svendsen,et al.  Inflammation in the genesis and perpetuation of atrial fibrillation. , 2005, European heart journal.

[4]  D. Kremastinos,et al.  Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. , 2005, The American journal of cardiology.

[5]  S. Petersen,et al.  Troponin Elevation After Percutaneous Coronary Intervention Directly Represents the Extent of Irreversible Myocardial Injury: Insights From Cardiovascular Magnetic Resonance Imaging , 2005, Circulation.

[6]  F. Apple,et al.  Cardiac troponin and creatine kinase MB monitoring during in-hospital myocardial reinfarction. , 2005, Clinical chemistry.

[7]  David O. Martin,et al.  C-Reactive protein level and recurrence of atrial fibrillation after electrical cardioversion , 2005 .

[8]  I. Kubota,et al.  C-Reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation , 2005, Heart and Vessels.

[9]  M. Roea,et al.  Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes , 2004 .

[10]  Samin K. Sharma,et al.  Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. , 2004, The American journal of cardiology.

[11]  B. Nallamothu,et al.  Periprocedural myocardial infarction and mortality: causality versus association. , 2003, Journal of the American College of Cardiology.

[12]  J. Ioannidis,et al.  Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. , 2003, Journal of the American College of Cardiology.

[13]  J. Ioannidis,et al.  Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. , 2003, Journal of the American College of Cardiology.

[14]  P. Serruys,et al.  Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention , 2002 .

[15]  E. Topol,et al.  Death Following Creatine Kinase-MB Elevation After Coronary Intervention: Identification of an Early Risk Period: Importance of Creatine Kinase-MB Level, Completeness of Revascularization, Ventricular Function, and Probable Benefit of Statin Therapy , 2002, Circulation.

[16]  V. Hasselblad,et al.  Prognostic significance of elevated troponin I after percutaneous coronary intervention. , 2002, Journal of the American College of Cardiology.

[17]  E. Topol,et al.  Frequency and long-term impact of myonecrosis after coronary stenting. , 2002, European heart journal.

[18]  M. Leon,et al.  Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts , 2002, Circulation.

[19]  M. Simoons,et al.  Minor Myocardial Damage and Prognosis: Are Spontaneous and Percutaneous Coronary Intervention–Related Events Different? , 2002, Circulation.

[20]  Deepak L. Bhatt,et al.  Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes , 2001, Circulation.

[21]  G. Stone,et al.  Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention: A Device-Specific Analysis of 7147 Patients , 2001, Circulation.

[22]  R. Kim,et al.  Visualization of Discrete Microinfarction After Percutaneous Coronary Intervention Associated With Mild Creatine Kinase-MB Elevation , 2001, Circulation.

[23]  A. Wu,et al.  Quality Specifications for Cardiac Troponin Assays , 2001, Clinical chemistry and laboratory medicine.

[24]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[25]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[26]  G. Stone,et al.  Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. , 2000, The American journal of cardiology.

[27]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[28]  Samin K. Sharma,et al.  Final results of the Balloon vs Optimal Atherectomy Trial (BOAT) , 1998, Circulation.

[29]  R. Califf,et al.  Myonecrosis after revascularization procedures. , 1998, Journal of the American College of Cardiology.

[30]  R. Bonow,et al.  Prognostic implication of creatine kinase elevation following elective coronary artery interventions. , 1997, JAMA.

[31]  E. Topol,et al.  Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. , 1996, Circulation.

[32]  V. Gökhan Cin,et al.  The prognostic value of serum troponin T in unstable angina. , 1996, International journal of cardiology.